PubRank

P Reiss

Author PubWeight™ 149.83‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003 7.94
2 A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA 1998 7.00
3 Failure of zidovudine prophylaxis after accidental exposure to HIV-1. N Engl J Med 1990 3.61
4 Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999 3.41
5 Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 2003 3.23
6 Clinical significance of small-intestinal microsporidiosis in HIV-1-infected individuals. Lancet 1991 2.87
7 Diagnosis of intestinal and disseminated microsporidial infections in patients with HIV by a new rapid fluorescence technique. J Clin Pathol 1993 2.52
8 The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med 2006 2.38
9 Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis 2004 2.26
10 Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000 2.14
11 High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS 2001 2.03
12 Cardio- and cerebrovascular events in HIV-infected persons. AIDS 2004 1.98
13 Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group. Lancet 1999 1.95
14 The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era. Clin Infect Dis 2013 1.91
15 Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study. Lancet 1998 1.88
16 Pulmonary tuberculosis due to Mycobacterium microti in a human immunodeficiency virus-infected patient. Clin Infect Dis 1998 1.87
17 Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways. AIDS 2001 1.81
18 Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 2001 1.81
19 Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS 1998 1.81
20 Diagnosis of Enterocytozoon bieneusi microsporidiosis in AIDS patients by recovery of spores from faeces. Lancet 1990 1.67
21 Response to cytarabine in progressive multifocal leucoencephalopathy in AIDS. Lancet 1991 1.62
22 The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons. J Infect Dis 2001 1.62
23 Conversion rate towards a syncytium-inducing (SI) phenotype during different stages of human immunodeficiency virus type 1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis. J Infect Dis 1999 1.61
24 Effects of protease inhibitors on the course of CMV retinitis in relation to CD4+ lymphocyte responses in HIV+ patients. Br J Ophthalmol 1998 1.57
25 The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. AIDS 2000 1.56
26 European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med 2008 1.54
27 Ganciclovir/foscarnet for cytomegalovirus meningoencephalitis in AIDS. Lancet 1992 1.50
28 [Mycobacterium avium infection in HIV-infected patients: epidemiology, diagnosis, prevention and treatment]. Ned Tijdschr Geneeskd 1997 1.44
29 Severe bacterial non-aids infections in HIV-positive persons: incidence rates and risk factors. J Infect 2013 1.43
30 Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study(*). HIV Med 2011 1.43
31 Spontaneous regression of Ki-1 positive T-cell non-Hodgkin's lymphoma in a patient with HIV infection. Br J Haematol 1992 1.39
32 Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons. J Infect Dis 1999 1.32
33 Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA study. Ann Intern Med 1999 1.30
34 Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS 1997 1.30
35 Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups. N Engl J Med 2001 1.27
36 The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis. HIV Med 2011 1.26
37 Dissemination of the AHCPR clinical practice guideline in community health centres. Tob Control 2002 1.24
38 Lamin A/C mutations with lipodystrophy, cardiac abnormalities, and muscular dystrophy. Neurology 2002 1.23
39 Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma. Am J Clin Oncol 2001 1.22
40 Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS 2001 1.18
41 Regional differences in use of antiretroviral agents and primary prophylaxis in 3122 European HIV-infected patients. EuroSIDA Study Group. J Acquir Immune Defic Syndr Hum Retrovirol 1997 1.14
42 Evaluation of HIV protease inhibitor use and the risk of sudden death or nonhemorrhagic stroke. J Infect Dis 2012 1.13
43 Immunopathology as a result of highly active antiretroviral therapy in HIV-1-infected patients. AIDS 1999 1.12
44 Retinal and extraocular cytomegalovirus end-organ disease in HIV-infected patients in Europe: a EuroSIDA study, 1994-2001. Eur J Clin Microbiol Infect Dis 2004 1.10
45 Antigen-driven CD4+ T cell and HIV-1 dynamics: residual viral replication under highly active antiretroviral therapy. Proc Natl Acad Sci U S A 1999 1.08
46 Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine. AIDS 2001 1.07
47 Failure to maintain high-dose treatment regimens during long-term use of zidovudine in patients with symptomatic human immunodeficiency virus type 1 infection. Genitourin Med 1990 1.04
48 Foscarnet and penile ulceration. Lancet 1990 1.04
49 Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. INCAS Study Group. AIDS 1999 1.04
50 A retrospective, cohort-based survey of patients using twice-daily indinavir + ritonavir combinations: pharmacokinetics, safety, and efficacy. J Acquir Immune Defic Syndr 2001 1.00
51 Cellular proviral HIV type 1 DNA load persists after long-term RT-inhibitor therapy in HIV type 1 infected persons. AIDS Res Hum Retroviruses 1998 0.99
52 Value of different assays for detection of human cytomegalovirus (HCMV) in predicting the development of HCMV disease in human immunodeficiency virus-infected patients. J Clin Microbiol 2000 0.98
53 Regression of AIDS-related Kaposi's sarcoma associated with clearance of human herpesvirus-8 from peripheral blood mononuclear cells following initiation of antiretroviral therapy. AIDS 1998 0.98
54 A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study. HIV Med 2010 0.98
55 Improvement of chronic diarrhoea in patients with advanced HIV-1 infection during potent antiretroviral therapy. AIDS 1998 0.98
56 Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction. Clin Infect Dis 2008 0.97
57 HIV-associated adipose redistribution syndrome as a selective autonomic neuropathy. Lancet 2003 0.96
58 Declining number of patients with cryptococcosis in the Netherlands in the era of highly active antiretroviral therapy. AIDS 2000 0.95
59 High-dose interferon-alpha2a exerts potent activity against human immunodeficiency virus type 1 not associated with antitumor activity in subjects with Kaposi's sarcoma. J Infect Dis 1997 0.95
60 Comparison of the plasma pharmacokinetics and renal clearance of didanosine during once and twice daily dosing in HIV-1 infected individuals. AIDS 1998 0.94
61 Diarrhoea in HIV-infected patients: no evidence of cytokine-mediated inflammation in jejunal mucosa. AIDS 1995 0.92
62 Normal T-cell telomerase activity and upregulation in human immunodeficiency virus-1 infection. Blood 1999 0.91
63 Use of competitive polymerase chain reaction to determine HIV-1 levels in response to antiviral treatments. AIDS 1993 0.91
64 Resumption of HIV antigen production during continuous zidovudine treatment. Lancet 1988 0.91
65 Induction-maintenance antiretroviral therapy: proof of concept. AIDS 1998 0.90
66 High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication. J Infect Dis 1997 0.89
67 Dose-finding study of a once-daily indinavir/ritonavir regimen. J Acquir Immune Defic Syndr 2000 0.89
68 Toxicity and drug exposure in a quadruple drug regimen in HIV-1 infected patients participating in the ADAM study. AIDS 2000 0.89
69 The proteolytic specificity of the natural enediyne-containing chromoproteins is unique to each chromoprotein. Chem Biol 1995 0.88
70 Patterns of T-cell repopulation, virus load reduction, and restoration of T-cell function in HIV-infected persons during therapy with different antiretroviral agents. J Acquir Immune Defic Syndr Hum Retrovirol 1997 0.88
71 Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study. HIV Med 2003 0.87
72 Assisted reproductive technologies to establish pregnancies in couples with an HIV-1-infected man. Neth J Med 2009 0.87
73 Implementing the number needed to harm in clinical practice: risk of myocardial infarction in HIV-1-infected patients treated with abacavir. HIV Med 2009 0.84
74 Restoration of the toxoplasmastatic activity of monocytes from AIDS patients during in vivo treatment with interferon-gamma. J Infect Dis 1993 0.84
75 Advanced chronic kidney disease, end-stage renal disease and renal death among HIV-positive individuals in Europe. HIV Med 2013 0.84
76 [Metabolic side effects of antiretroviral therapy]. Ned Tijdschr Geneeskd 2008 0.83
77 A simplified combination antiretroviral therapy regimen enhances adherence, treatment satisfaction and quality of life: results of a randomized clinical trial. HIV Med 2013 0.83
78 Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study). HIV Med 2011 0.83
79 Sound-induced displacement responses in the plane of the organ of Corti in the isolated guinea-pig cochlea. Hear Res 1995 0.82
80 Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equations. HIV Med 2014 0.82
81 Evaluation of Subcutaneous Proleukin (interleukin-2) in a Randomized International Trial (ESPRIT): geographical and gender differences in the baseline characteristics of participants. HIV Clin Trials 2006 0.82
82 Favourable effect of chemotherapy on clinical symptoms and human herpesvirus-8 DNA load in a patient with Kaposi's sarcoma presenting with fever and anemia. Eur J Clin Microbiol Infect Dis 1999 0.82
83 [LAV/HTLV-III infection after a one-time sexual contact with an AIDS patient]. Ned Tijdschr Geneeskd 1985 0.82
84 Surgical resection is necessary to maximize tumor control in function-preserving, aggressive chemoradiation protocols for advanced squamous cancer of the head and neck (stage III and IV). Ann Surg Oncol 2001 0.81
85 Plasma lipid concentrations after 1.5 years of exposure to nevirapine or efavirenz together with stavudine and lamivudine. HIV Med 2006 0.81
86 Pharmacokinetics, food intake requirements and tolerability of once-daily combinations of nelfinavir and low-dose ritonavir in healthy volunteers. Br J Clin Pharmacol 2003 0.81
87 Results of long-term follow-up of HIV-infected patients treated with lamivudine monotherapy, followed by a combination of lamivudine and zidovudine. Antivir Ther 1997 0.81
88 AIDS dementia complex and didanosine. Lancet 1994 0.80
89 T-cell progenitor function during progressive human immunodeficiency virus-1 infection and after antiretroviral therapy. Blood 2000 0.80
90 Expression of granzyme B by cytotoxic T lymphocytes in the lymph nodes of HIV-infected patients. AIDS Res Hum Retroviruses 1997 0.80
91 A comparison of estimated glomerular filtration rates using Cockcroft-Gault and the Chronic Kidney Disease Epidemiology Collaboration estimating equations in HIV infection. HIV Med 2013 0.80
92 Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients. HIV Med 2011 0.79
93 Selective inhibition of syncytium-inducing and nonsyncytium-inducing HIV-1 variants in individuals receiving didanosine or zidovudine, respectively. J Clin Invest 1997 0.79
94 A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe. Infection 2014 0.79
95 Reproduction and fertility in human immunodeficiency virus type-1 infection. Hum Reprod Update 2006 0.79
96 Update on opportunistic infections. AIDS 1991 0.79
97 Temporary increase in serum beta 2-microglobulin during treatment with interferon-alpha for AIDS-associated Kaposi's sarcoma. AIDS 1990 0.79
98 High rate of hepatitis C virus (HCV) recurrence in HIV-infected individuals with spontaneous HCV RNA clearance. HIV Med 2014 0.79
99 Pyrimethamine alone as maintenance therapy for central nervous system toxoplasmosis in 38 patients with AIDS. J Acquir Immune Defic Syndr 1992 0.78
100 T cell expansions in lymph nodes and peripheral blood in HIV-1-infected individuals: effect of antiretroviral therapy. AIDS 2001 0.78
101 Mitochondrial DNA assessment in adipocytes and peripheral blood mononuclear cells of HIV-infected patients with lipodystrophy according to a validated case definition. HIV Med 2007 0.78
102 Disseminated cat-scratch disease in a patient with AIDS. AIDS 1989 0.78
103 A comparison of computational models with and without genotyping for prediction of response to second-line HIV therapy. HIV Med 2014 0.77
104 Near-field optical imaging with a CdSe single nanocrystal-based active tip. Opt Express 2006 0.77
105 Durable HIV-1 suppression with indinavir after failing lamivudine-containing double nucleoside therapy: a randomized controlled trial. Antivir Ther 2001 0.77
106 Once-daily indinavir plus ritonavir: preliminary results of the PIPO study. AIDS 2000 0.77
107 [A patient with a mild form of the acquired immunodeficiency syndrome (AIDS)]. Ned Tijdschr Geneeskd 1983 0.77
108 The serology and immunochemistry of HIV-induced platelet-bound immunoglobulin. Blut 1989 0.77
109 Invasive external otitis caused by Aspergillus fumigatus in two patients with AIDS. AIDS 1991 0.77
110 Seroconversion to HIV-1 rev- and tat-gene-encoded proteins. AIDS 1989 0.77
111 Longer prior exposure to zidovudine/lamivudine-containing combination antiretroviral therapy, age, and male gender are each associated with reduced subcutaneous adipose tissue. HIV Clin Trials 2012 0.77
112 Differential CD4 T-cell response in HIV-1-infected patients using protease inhibitor-based or nevirapine-based highly active antiretroviral therapy. HIV Med 2004 0.76
113 Low-grade thrombotic thrombocytopenic purpura associated with HIV-1 infection. Br J Haematol 1993 0.76
114 [Zidovudine therapy in 141 patients with symptoms of HIV infection; a multicenter study]. Ned Tijdschr Geneeskd 1990 0.76
115 [Pneumocystis carinii infection during prophylaxis with nebulized pentamidine in a patient with AIDS]. Ned Tijdschr Geneeskd 1991 0.76
116 HIV-1 P24 antigenaemia does not predict time of survival in AIDS patients. Genitourin Med 1990 0.75
117 The effects of enfuvirtide therapy on body composition and metabolic parameters over 48 weeks in the TORO body imaging substudy. HIV Med 2011 0.75
118 Suppressive therapy for cryptococcal meningitis. N Engl J Med 1992 0.75
119 Impact of co-morbidity and aging on health-related quality of life in HIV-positive and HIV-negative individuals. AIDS 2017 0.75
120 Additive or sequential nucleoside analogue therapy compared with continued zidovudine monotherapy in human immunodeficiency virus-infected patients with advanced disease does not prolong survival: an observational study. J Infect Dis 1997 0.75
121 Baseline lipid levels rather than the presence of reported body shape changes determine the degree of improvement in lipid levels after switching to atazanavir. HIV Clin Trials 2009 0.75
122 Seroconversion to HIV-1 negative regulation factor. Lancet 1988 0.75
123 Rhyming and conceptual relationships in a free-recall task with retardates. Am J Ment Defic 1968 0.75
124 Nevirapine plus didanosine: once or twice daily combination? J Acquir Immune Defic Syndr 2000 0.75
125 Activation of the cytokine network in a patient with AIDS and the recalcitrant erythematous desquamating disorder. Clin Infect Dis 1994 0.75
126 Photodynamic therapy in AIDS-related cutaneous Kaposi's sarcoma. J Acquir Immune Defic Syndr Hum Retrovirol 1995 0.75
127 Favourable SVR12 rates with boceprevir or telaprevir triple therapy in HIV/HCV coinfected patients. Neth J Med 2015 0.75
128 [Yeast infections in patients with immunologic disorders]. Ned Tijdschr Geneeskd 1995 0.75
129 Continued therapy with HIV-1 protease inhibitors, despite previous hypersensitivity reactions, through coadministration of prednisone. Scand J Infect Dis 1998 0.75
130 Estimates of the virological benefit of antiretroviral therapy are both assay- and analysis-dependent. AIDS 1998 0.75
131 Tolerability and activity of a new recombinant interferon-alpha B/D hybrid in patients with HIV-1 infection. Antivir Ther 1996 0.75
132 The J = 1 para levels of the v = 0 to 6 np singlet Rydberg series of molecular hydrogen revisited. J Chem Phys 2012 0.75
133 Erratum: Large Fermi Surface of Heavy Electrons at the Border of Mott Insulating State in NiS2. Sci Rep 2016 0.75
134 The transition probabilities from the ground state to the excited J = 0 1Σu(+) levels of H2: measurements and ab initio quantum defect study. J Chem Phys 2011 0.75
135 Pharmacokinetic interaction study of indinavir/ritonavir and the enteric-coated capsule formulation of didanosine in healthy volunteers. J Clin Pharmacol 2005 0.75
136 Kaposi's sarcoma and AIDS. Nature 1990 0.75
137 Special education for the mentally retarded in Japan. Ment Retard 1969 0.75
138 Treatment of AIDS-related non-Hodgkin's lymphoma with chemotherapy (CNOP) and r-hu-G-CSF: clinical outcome and effect on HIV-1 viral load. Ann Oncol 1998 0.75
139 [Twenty years of combination antiretroviral therapy for HIV infection in the Netherlands: progression and new challenges]. Ned Tijdschr Geneeskd 2017 0.75
140 Corrections. Lancet Infect Dis 2015 0.75
141 Implications of Piaget's developmental psychology for mental retardation. Am J Ment Defic 1967 0.75
142 [HIV-infection and diarrhea: diagnosis and treatment]. Ned Tijdschr Geneeskd 1993 0.75
143 The J = 2 ortho levels of the v = 0 to 6 np singlet Rydberg series of molecular hydrogen revisited. J Chem Phys 2012 0.75
144 Lack of activity of zidovudine in AIDS-associated Kaposi's sarcoma. AIDS 1989 0.75
145 [HIV-related non-Hodgkin lymphoma in 45 patients; a retrospective analysis]. Ned Tijdschr Geneeskd 1993 0.75
146 Mapping the 3D distribution of CdSe nanocrystals in highly oriented and nanostructured hybrid P3HT-CdSe films grown by directional epitaxial crystallization. Nanoscale 2012 0.75
147 [HIV-1 therapy in the Netherlands; virological and immunological response to antiretroviral therapy]. Ned Tijdschr Geneeskd 2001 0.75
148 Risk of non-AIDS-defining events among HIV-infected patients not yet on antiretroviral therapy. HIV Med 2015 0.75